HBB p.Ala28Ser
c.82G>T · rs35424040 · VCV15239
ClinGen expert panel — Hemoglobinopathy VCEP
Pathogenic for beta-thalassemia HBB/LCRB. Applied ACMG criteria (verbatim):
PP1_Strong PM2_Supporting PS3_Supporting PS4_Moderate PP3 PM3
Curation rationale (ClinGen, verbatim)
The c.82G>T (p.Ala28Ser) variant is located in the HBB gene. This variant has been reported in 12 unrelated individuals displaying a hematological phenotype consistent with beta thalassemia trait (reduced MCV and MCH with normal or increased RBC count), giving a total score of 2.15 [PS4_M; PMID: 7104238; 3955238; The Hemoglobinopathies Laboratory, Department of Human and Clinical Genetics, Leiden University Medical Center; Department of Medical Genetics, National and Kapodistrian University of Athens]. This variant has been reported to segregate with a beta-thalassemia intermedia phenotype in 8 affected family members from 4 families. The total number of unaffected segregations is 8 with a LOD score of 5.81 [PP1_S; PMID:7104238; 3955238; 25332589; 30777047; 17949282]. It was detected in combination with a pathogenic variant in one affected individual, confirmed in trans by DNA studies, and found in a homozygous state in another, both presenting with a beta-thalassemia intermedia phenotype. Total PM3 points are 1.5 [PM3; PMID:3955238; 25332589; Variation ID: 15438]. Hemoglobin biosynthesis assay showed a change in biosynthetic ratio of globins in a heterozygous sample (β/α ratio 0.45-0.55), indicating that this variant impacts protein function. In addition, in vitro splicing assay showed that this variant leads to abnormal RNA processing by creating/utilizing a cryptic splice site in exon 1 of HBB [PS3_P; PMID:6733281; 7104238; 7173395]. The computational predictor SpliceAI gives a Δ score of 0.79 for donor gain in exon 3, which is above the VCEP threshold >0.3, predicting that this variant may affect splicing by disrupting the donor splice site of intron 3 in HBB [PP3]. The minor allele frequency in gnomAD v4.1 is 0.000002479 (4/1613406) alleles, which is lower than the ClinGen Hemoglobinopathy VCEP threshold <0.0001 for PM2_Supporting, and therefore meets this criterion [PM2_P]. In summary, this variant meets the criteria to be classified as pathogenic for beta thalassemia (MONDO:0013517) in an autosomal recessive manner based on the ACMG/AMP criteria applied, as specified by the ClinGen Hemoglobinopathy VCEP (specification version 1.0.0): PP1_S, PS4_M, PM3, PM2_P, PP3, PS3_P.
ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.
Computational evidence
| Protein change | ||
| AlphaMissense | 0.1656 | likely benign ⚠ discordant with ClinVar |
|---|---|---|
| REVEL | 0.641 | indeterminate |
| SaProt | LLR -10.07 | damaging |
| ⇒ SaProt calls this damaging; AlphaMissense does not; REVEL makes no call. | ||
| Splicing | ||
| SpliceAI | Δ0.79 | donor gain · deltas |
| Pangolin | Δ0.64 | gain · loss 0.36 · agrees with SpliceAI · independent |
| Constraint at this position | ||
| Conservation | phyloP -0.99 | GERP -2.1 |
| Regional constraint | o/e 0.88 | unconstrained · MANE · 1,420 bp · p 0.11 · regional, not allelic |
| Overall | ||
| CADD | 24.4 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| African / African-Americangrpmax | 0.00267% | 37,454 |
| European (non-Finnish) | 0.00017% | 589,699 |
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- HBB
- Protein
- p.Ala28Ser
- Coding
- c.82G>T
- MANE Select
- NM_000518
- dbSNP
- rs35424040
- Type
- single nucleotide variant
- Location
- chr11:5226940 (GRCh38)
- Gene constraint
- LOEUF 1.964 · pLI <0.01 (gnomAD)
- Structure
- AlphaFold pLDDT 97.09 · 350 PDB
- Residue 28
- a UniProt-annotated variant site (in volga/drenthe; unstable); a UniProt-annotated variant site (in knossos); a UniProt-annotated variant site (in grange-blanche; o(2) affinity up); an α-helix; the globin domain
Disease context
beta-thalassemia HBB/LCRB — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: Heinz body anemiadominant beta-thalassemiasickle cell diseasebeta thalassemiahereditary persistence of fetal hemoglobinmalaria, susceptibility tohemoglobinopathyerythrocytosis, familial, 6
Similar variants
- HBB p.Ala28Thr Likely pathogenic ⚠ same residue
- HBB p.Ala28Asp Pathogenic ★ same residue
- HBB p.Ala28Val Uncertain significance ★ ⚠ same residue
- HBB p.Ala28= Likely benign ★ same residue
- HBB c.316-146T>G Pathogenic ★★★ same condition
- HBB c.316-197C>T Pathogenic ★★★ same condition
- HBB c.92+5G>C Pathogenic ★★★ same condition
- HBB c.-78A>C Pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/hbb-p-ala28ser (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown